Day: December 13, 2024

Please see the attached news releaseAttachmentJennie Younger Resignation

 Jean-Marc Huët to be appointed as Chair to succeed Maarten Das Retirement of Maarten Das as non-executive member and Chair Reappointment of Alexander de Carvalho as non-executive memberAmsterdam, 13 December 2024 – The Board of Directors of Heineken Holding N.V. will propose at the Annual General Meeting of Shareholders (AGM) in April 2025 to appoint Jean-Marc Huët as non-executive member of the Board of Directors of Heineken Holding N.V., for the maximum period of four years, i.e. until the AGM in 2029. The Board of Directors has appointed Mr Huët as Chair of the Board of Directors, conditional upon his appointment as non-executive member of the Board of Directors. Jean-Marc Huët (1969) is a Dutch national. Mr Huët holds an MBA from INSEAD (Fontainebleau, France) and a bachelor’s degree from Dartmouth College (New Hampshire,...

The rating agency Moody’s Ratings affirmed Coop Pank’s Credit rating and raised outlook to positive. Long- and short-term deposit rating remained on the level of Baa2 and outlook changed to positive, from stable. According to Paavo Truu, CFO of Coop Pank, the affirmation of the credit rating at the current level confirms that the bank is trustworthy with solid capital base and high quality of the loan portfolio even in difficult times and has shown good profitability. “The affirmation of the rating and raising outlook to positive gives private individuals and businesses additional confidence to become a customer of Coop Pank and keep their money in a domestic financial institution,” said Truu. Ratings affirmed by Moody’s Ratings for Coop Pank AS:Foreign- and local currency long- and short-term bank deposit rating Baa2/Prime-2 Long-...

Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosisDesignation is based on positive results from the HERCULES study in adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS) Tolebrutinib is the first and only brain-penetrant BTK inhibitor in MS to be designated Breakthrough Therapy by the FDA Paris, December 13, 2024. The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS). This is based on positive results from the HERCULES phase 3 study, demonstrating that tolebrutinib delayed the time to onset of 6-month confirmed disability progression (CDP), by 31% compared to placebo (HR 0.69; 95% CI 0.55-0.88; p=0.0026),...

The new cobas 6800/8800 systems 2.0 enhances throughput, run flexibility, enables sample prioritisation and is available as an upgrade to existing systems in healthcare settings around the world. Laboratories can now perform a wider range of tests on a single solution, simplifying laboratory logistics and helping to optimise the use of resources.Basel, 13 December 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the CE certification of the new cobas® 6800/8800 systems 2.0. The update significantly enhances the efficiency of laboratories by optimising resources, reducing downtime, consolidating test menus, and increasing throughput. These improvements ultimately promise a more streamlined diagnostics experience for healthcare professionals and their patients. “This update marks another significant milestone for Roche,”...

Lassila & Tikanoja plcStock exchange release                13 December 2024 at 8:10 Lassila & Tikanoja plc’s Board of Directors resolved on new performance period 2025—2027 for the company’s performance share plan The Board of Directors of Lassila & Tikanoja Plc established a Performance Share Plan 2023-2027 in 2022 for the company’s key employees. Performance Share Plan 2023-2027 includes three performance periods, covering the calendar years 2023—2025, 2024—2026 and 2025–2027. The key terms of the Performance Share Plan 2023–2027 were published by stock exchange release on 15 December 2022. The Board of Directors of Lassila & Tikanoja has resolved on the target group, the amount of the possible rewards and the performance criteria for the performance period 2025—2027. During the performance period 2025–2027,...

Vabysmo PFS is the first and only prefilled syringe containing a bispecific antibody, offering a convenient alternative to currently available Vabysmo vials Vabysmo has demonstrated rapid and robust vision and anatomical improvements in neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) and retinal vein occlusion (RVO) The ready-to-use Vabysmo PFS is co-packaged with the only CE-marked needle specifically designed for intravitreal injectionBasel, 13 December 2024– Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency has approved Vabysmo® (faricimab) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of neovascular or ‘wet’ age-related macular degeneration (nAMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). Together,...

Lassila & Tikanoja Plc Stock exchange release Inside information 13 December 2024 at 8:05 a.m. Inside information: Lassila & Tikanoja will recognise impairments and make provisions of approximately EUR 28 million in total relating to its Swedish facility services business In its Q4 2024 reporting, Lassila & Tikanoja will recognise impairments and make provisions of approximately EUR 28 million in total (before taxes) relating to its Swedish facility services business. The impairments and provisions will be reported as items affecting comparability. The net sales and operating profit development of the Swedish facility services business has been weaker than anticipated. Based on routine impairment testing, an impairment of approximately EUR 23 million will be recognised in the consolidated goodwill related to Facility Services...

NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the pricing of an underwritten public offering of 10,000,001 shares of its common stock at a price to the public of $6.00 per share and pre-funded warrants to purchase up to an aggregate of 3,333,333 shares of its common stock at a price to the public of $5.99 per pre-funded warrant to purchase one share of the common stock, which represents the per share public offering price for the common stock less the $0.01 per share exercise price for each such pre-funded warrant. The gross proceeds from the offering to Candel are expected to be approximately $80 million, before deducting underwriting...